Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-04-03 Proxy Solicitation & In…
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (AGM) for Egetis Therapeutics AB. It contains the agenda, proposals for board elections, remuneration, and instructions for shareholder participation (in-person and advance voting). This document is a proxy statement/notice sent to shareholders to inform them of the upcoming meeting and solicit their votes on specific items, which fits the definition of a Proxy Solicitation & Information Statement.
2025-04-03 English
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice ('Kallelse') for an Annual General Meeting (Årsstämma) for Egetis Therapeutics AB. It contains the agenda, proposals for board elections, remuneration, and voting instructions for shareholders. This document is the official invitation and proxy material for the upcoming AGM, which falls under the category of Proxy Solicitation & Information Statement.
2025-04-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-End Report) for the period January-December 2024. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet data, as well as detailed management commentary on business operations, clinical trial updates (ReTRIACt), and strategic outlook. It is a full financial report for a period shorter than a full fiscal year (in the context of the reporting cycle) or a year-end summary, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis. FY 2024
2025-02-26 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 95% confidence The document is a 'Year-End Report' for the period January-December 2024, containing comprehensive financial statements, management commentary, operational updates, and a financial overview table. It provides substantive financial data and analysis for the full fiscal year, which aligns with the definition of an Interim/Quarterly Report (IR) in the context of a year-end summary report that is not a full 10-K/Annual Report. FY 2024
2025-02-26 English
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency
Regulatory Filings Classification · 95% confidence The document is a press release dated February 13, 2025, announcing that the European Commission has approved Egetis' drug, Emcitate®. It details the approval, the indication, CEO comments, clinical trial background, and regulatory context (EMA recommendation, Orphan Drug Designation). This type of announcement, focusing on a significant corporate event (drug approval) and providing key financial/operational context, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about a major corporate milestone (drug approval) rather than just a general regulatory update or a report itself, it aligns best with an Earnings Release (ER) which often includes major operational news alongside financial context, or potentially a Regulatory Filing (RNS) if it were less comprehensive. Given the depth of the announcement regarding the approval and its significance ("single most important milestone"), it functions as a major corporate update. However, since the definitions do not explicitly cover 'Drug Approval Announcement', we must choose the closest fit. It is not a 10-K, AR, IR, or CT. It is a formal announcement of a major event. In many databases, major corporate news releases that aren't strictly financial results are often categorized as Regulatory Filings (RNS) or sometimes grouped with Earnings Releases (ER) if they occur around reporting periods. Since this is a standalone, material announcement, and it is not a report itself (it mentions an attachment/PDF), RNS is the most appropriate fallback for a significant, non-standard filing, or ER if we interpret 'major operational news' as fitting that bucket. Given the context of a press release announcing a major regulatory event, RNS (General regulatory announcements and fallback category) is the safest classification when a specific 'Drug Approval' category is missing. The document length (7940 chars) is substantial, suggesting it is more than just a brief notice, but it is still an announcement, not the underlying regulatory document itself.
2025-02-13 English
EU-kommissionen godkänner Egetis Emcitate® (tiratricol) som den första och enda behandlingen för patienter med MCT8-brist
Regulatory Filings Classification · 95% confidence The document is a press release dated February 13, 2025, announcing that the European Commission has approved Egetis Therapeutics' drug Emcitate® for MCT8 deficiency. It details the significance of the approval, comments from the CEO, clinical trial background, and future plans (pricing negotiations, launch timeline). The text concludes with contact information and a statement about the information being made public under the EU Market Abuse Regulation, followed by an explicit link to a PDF document titled similarly to the press release itself. Since the document is a formal announcement detailing a major corporate event (drug approval) and is not merely stating that a report is attached or available (it contains the full substance of the announcement), it is best classified as an Earnings Release (ER) or a general Regulatory Filing (RNS). Given that this is a major, time-sensitive announcement of a regulatory milestone, and it is not a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release, often used broadly for major operational/regulatory news releases) or 'RNS' (Regulatory News Service/General Regulatory Filing) are the closest fits. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a regulatory/operational highlight, 'RNS' (Regulatory Filings - general fallback) is the most appropriate category for a non-financial results press release announcing a major regulatory event, especially since it doesn't fit the specific definitions of LTR, CAP, or DIV. However, in many databases, major press releases announcing key milestones like drug approvals are often categorized under 'ER' if they are the primary communication vehicle, or 'RNS' as a catch-all. Given the structure and content (major corporate news release), I will classify it as RNS as it is a general regulatory announcement that doesn't fit the other specific categories perfectly, although it shares characteristics with an ER.
2025-02-13 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.